Wednesday, July 4, 2018

Roche Reports Positive Clinical Results, But The Market Is Unimpressed

Roche's (OTCQX:RHHBY) plans to leverage Tecentriq as its next cancer blockbuster and offset steep looming biosimilar sales erosion have been looking shakier and shakier as the company continues to post okay-but-great data from multiple trials, while chief rival Merck (MRK) continues to post strong Keytruda data. While two recent positive trial read-outs on Tecentriq in lung cancer and breast cancer are certainly welcome, they're not likely going to change the tide of sentiment, and management has work to do to convince the Street it's not an also-ran in the making.

Click here for more:
Roche Reports Positive Clinical Results, But The Market Is Unimpressed

No comments: